Literature DB >> 19802028

Reduced-intensity conditioning and umbilical cord blood transplantation in adults.

C Cutler1, K Ballen.   

Abstract

Reduced-intensity conditioning (RIC) preparative regimens are now widely used in umbilical cord blood (UCB) transplantation. Developed to reduce the rate of transplant-related morbidity and mortality as in adult stem cell donor transplantation, they are becoming more widely accepted. Results from RIC UCB series show a shortened time to engraftment, ranging from 12 to 24 days, with rates of TRM that generally do not exceed the rates seen with myeloablative UCB transplantation. There does not seem to be a convincing trend toward an increase in the rate of malignant relapse after RIC UCB transplantation, despite the lower intensity of the conditioning regimen. In this review, the results from several RIC UCB series are reviewed, comparisons with myeloablative UCB experiences are made and hypotheses regarding the engraftment potential of UCB after RIC regimens are discussed. In addition, a strategy for the optimal use of RIC regimens and UCB transplantation is presented.

Entities:  

Mesh:

Year:  2009        PMID: 19802028     DOI: 10.1038/bmt.2009.283

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  10 in total

1.  Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.

Authors:  Junya Kanda; David A Rizzieri; Cristina Gasparetto; Gwynn D Long; John P Chute; Keith M Sullivan; Ashley Morris; Clayton A Smith; Donna E Hogge; Janet Nitta; Kevin Song; Donna Niedzwiecki; Nelson J Chao; Mitchell E Horwitz
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-22       Impact factor: 5.742

2.  Impact of 2 Gy γ-irradiation on the hallmark characteristics of human bone marrow-derived MSCs.

Authors:  Masaki Iwasa; Sumie Fujii; Aya Fujishiro; Taira Maekawa; Akira Andoh; Akifumi Takaori-Kondo; Tatsuo Ichinohe; Yasuo Miura
Journal:  Int J Hematol       Date:  2021-01-01       Impact factor: 2.490

3.  Feasibility of umbilical cord blood transplantation with a myeloablative, reduced toxicity-conditioning regimen.

Authors:  M Nishimoto; H Nakamae; M Nakamae; A Hirose; K Hagihara; H Koh; T Nakane; Y Terada; M Hino
Journal:  Bone Marrow Transplant       Date:  2014-04-07       Impact factor: 5.483

Review 4.  Ex vivo expansion of umbilical cord blood: where are we?

Authors:  Omar S Aljitawi
Journal:  Int J Hematol       Date:  2012-03-23       Impact factor: 2.490

5.  Optimizing cord blood selection.

Authors:  Annalisa Ruggeri
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

6.  Advances in cord blood transplants in adults.

Authors:  Phuong L Doan; Nelson J Chao
Journal:  F1000 Med Rep       Date:  2010-02-11

7.  Improved survival after single-unit cord blood transplantation using fludarabine and melphalan-based reduced-intensity conditioning for malignant lymphoma: impact of melphalan dose and graft-versus-host disease prophylaxis with mycophenolate mofetil.

Authors:  Kazuki Sakatoku; Sung-Won Kim; Hiroshi Okamura; Minoru Kanaya; Koji Kato; Satoshi Yamasaki; Naoyuki Uchida; Hikaru Kobayashi; Takahiro Fukuda; Nobuyuki Takayama; Jun Ishikawa; Hideyuki Nakazawa; Masatoshi Sakurai; Takashi Ikeda; Tadakazu Kondo; Satoshi Yoshioka; Toshihiro Miyamoto; Takafumi Kimura; Tatsuo Ichinohe; Yoshiko Atsuta; Eisei Kondo
Journal:  Ann Hematol       Date:  2022-10-05       Impact factor: 4.030

8.  Umbilical cord blood transplantation.

Authors:  Hong Hoe Koo; Hyo Seop Ahn
Journal:  Korean J Pediatr       Date:  2012-07-17

9.  A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies.

Authors:  M Gotoh; S Yoshizawa; S Katagiri; T Suguro; M Asano; T Kitahara; D Akahane; S Okabe; T Tauchi; Y Ito; K Ohyashiki
Journal:  Bone Marrow Transplant       Date:  2014-04-14       Impact factor: 5.483

10.  Phase II study of intrabone single unit cord blood transplantation for hematological malignancies.

Authors:  Makoto Murata; Yoshinobu Maeda; Masayoshi Masuko; Yasushi Onishi; Tomoyuki Endo; Seitaro Terakura; Yuichi Ishikawa; Chisako Iriyama; Yoko Ushijima; Tatsunori Goto; Nobuharu Fujii; Mitsune Tanimoto; Hironori Kobayashi; Yasuhiko Shibasaki; Noriko Fukuhara; Yoshihiro Inamoto; Ritsuro Suzuki; Yoshihisa Kodera; Tadashi Matsushita; Hitoshi Kiyoi; Tomoki Naoe; Tetsuya Nishida
Journal:  Cancer Sci       Date:  2017-06-29       Impact factor: 6.716

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.